BZ NOTE: Merrimack Pharmaceuticals, As Part Of Its Agreement With Ipsen For The Sale Of Its Oncology Assets Including ONIVYDE, Is Eligible To Receive Additional Payments With The Possibility Of Up To $450M Contingent Upon The Approval Of Potential New Indications For ONIVYDE In The U.S
BZ 注意：作爲與益普生簽訂的出售腫瘤資產協議（包括ONIVYDE）的一部分，梅里馬克製藥有資格獲得額外付款，但可能獲得高達4.5億美元的付款，前提是ONIVYDE在美國的潛在新適應症獲得批准